Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by Arbourmarkon Dec 02, 2021 7:59am
80 Views
Post# 34188941

RE:Calgary herald

RE:Calgary herald

Although the news was positive it was grey in my opinion and the markets need more clarity. I for one was expecting more meat in the news release and in this news article from Calgary sun. 


The market clearly demonstrated yesterday that it requires more answers from mana age meant.

1. How much is this phase 3 trial going to cost? $50-$100M is standard.

2. Does Arch need to raise capital, if so how much? Is there dilution coming?

3. Is the Canadian Government going to participate in funding, if so how much? We know they kicked in $6.7M for phase 2.

4 Are we moving to senior exchange like TSX or Nasdaq to attract Institutional investors, the TSXV is not well respected nor does it qualify for many institutional investors.

5. We are still waiting on the detailed published results from the independent review of phase 2

It is obvious that mananagement has been proactive lining up Sunnybrook and its network of 65 hospitals plus they have manufactured enough of their drug to complete the phase 3 trial.

In my opinion have more questions then answers at this point and will continue with this nefarious trading pattern with the same day traders knocking it up at the open walk it down through the day and back up in the last 30 minutes. Yesterday was actually first time in months that it actually continued to get walked down and closed near the low of the day. I do not buy that this was sell the news event, 100,000 shares traded is not evidence of that.

<< Previous
Bullboard Posts
Next >>